奥妥珠单抗治疗狼疮肾炎患者的肾脏结局与肾功能保护:NOBILITY 试验的事后分析
该事后分析基于 II 期 NOBILITY 试验,比较奥妥珠单抗(n=63)与安慰剂(n=62)联合吗替麦考酚酯和糖皮质激素治疗活动性狼疮肾炎的肾脏结局。奥妥珠单抗使复合肾脏结局风险降低 60%、狼疮肾炎复发风险降低 57%,并显著减缓 eGFR 下降。第 76 周时更多奥妥珠单抗组患者在小剂量泼尼松(≤7.5 mg/d)下达到完全肾脏缓解。
要点
- 奥妥珠单抗使复合肾脏结局风险降低 60%、狼疮肾炎复发风险降低 57%。
- 奥妥珠单抗使首次 eGFR 下降 30% 和 40% 的风险分别降低 80% 和 91%。
- 第 76 周时 38% 奥妥珠单抗组 vs 16% 安慰剂组在泼尼松≤7.5 mg/d 下达到完全肾脏缓解(P<0.01)。
核心结论
- NOBILITY 试验事后分析显示,与标准治疗相比,奥妥珠单抗治疗带来更优的肾功能保护和狼疮肾炎复发预防。
- 奥妥珠单抗组更多患者在第 76 周时以更少糖皮质激素用量达到完全肾脏缓解。
研究设计与样本
- II 期 NOBILITY 试验的事后分析,活动性狼疮肾炎患者随机接受奥妥珠单抗(n=63)或安慰剂(n=62)联合吗替麦考酚酯和糖皮质激素治疗。
主要发现
- 奥妥珠单抗使复合肾脏结局(治疗失败、血清肌酐加倍或死亡的复合终点)风险降低 60%。
- 奥妥珠单抗使狼疮肾炎复发风险降低 57%,使首次 eGFR 下降 30% 和 40% 的风险分别降低 80% 和 91%。
- 奥妥珠单抗组 eGFR 下降速度显著慢于安慰剂组,年化 eGFR 斜率优势为 4.1 ml/min/1.73 m2/年(95%CI 0.14-8.08)。
- 第 76 周时,38% 奥妥珠单抗组患者 vs 16% 安慰剂组患者在泼尼松≤7.5 mg/d 下达到完全肾脏缓解(P<0.01);第 104 周时差异未达统计学显著(38% vs 22%;P=0.06)。
关键数值与推荐
- 复合肾脏结局风险降低 60%(奥妥珠单抗组 vs 安慰剂组)。
- 狼疮肾炎复发风险降低 57%(奥妥珠单抗组 vs 安慰剂组)。
- 首次 eGFR 下降 30% 风险降低 80%、下降 40% 风险降低 91%(奥妥珠单抗组 vs 安慰剂组)。
- 年化 eGFR 斜率优势 4.1 ml/min/1.73 m2/年(95%CI 0.14-8.08,奥妥珠单抗组 vs 安慰剂组)。
- 第 76 周完全肾脏缓解(泼尼松≤7.5 mg/d):38% 奥妥珠单抗组 vs 16% 安慰剂组(P<0.01);第 104 周:38% vs 22%(P=0.06)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether adding obinutuzumab to standard-of-care lupus nephritis (LN) therapy could improve the likelihood of long-term preservation of kidney function and do so with less glucocorticoids. METHODS: Post hoc analyses of the phase II NOBILITY trial were performed. Time to unfavorable kidney outcome (a composite of treatment failure, doubling of serum creatinine, or death), LN flare, first 30% and 40% declines in estimated glomerular filtration rate (eGFR) from baseline, and chronic eGFR slope during the trial were compared between patients with active LN who were randomized to take obinutuzumab (n = 63) or placebo (n = 62) in combination with mycophenolate mofetil and glucocorticoids. The number of patients who achieved complete renal response (CRR) on 7.5 mg or less per day of prednisone was also determined. RESULTS: Obinutuzumab reduced the risk of developing the composite kidney outcome by 60%, LN flare by 57%, and first eGFR decline of 30% or 40% by 80% and 91%, respectively. Patients receiving obinutuzumab had a significantly slower decline in eGFR than patients receiving placebo, with an annualized eGFR slope advantage of 4.1 ml/min/1.73 m2 /year (95% confidence interval 0.14-8.08). Overall, 38% of patients receiving obinutuzumab compared with 16% of patients receiving placebo achieved CRR at week 76 while receiving 7.5 mg or less per day of prednisone (P < 0.01); at week 104, the difference did not achieve significance (38% vs 22%; P = 0.06). CONCLUSION: Post hoc analyses of NOBILITY demonstrated that compared with standard-of-care therapy, obinutuzumab treatment resulted in superior preservation of kidney function and prevention of LN flares. More patients achieved CRR at week 76 with less glucocorticoid use in the obinutuzumab group.
引用
- Rovin BH, Furie RA, Ross Terres JA, et al. Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis Rheumatol. 2023. PMID: 37947366. doi:10.1002/art.42734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。